Medicamen Biotech Limited

NSE MEDICAMEQ.NS

Medicamen Biotech Limited Return on Equity (ROE) for the year ending March 31, 2024: 5.28%

Medicamen Biotech Limited Return on Equity (ROE) is 5.28% for the year ending March 31, 2024, a -31.19% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Medicamen Biotech Limited Return on Equity (ROE) for the year ending March 31, 2023 was 7.67%, a -24.54% change year over year.
Medicamen Biotech Limited Return on Equity (ROE) for the year ending March 31, 2022 was 10.17%, a 11.43% change year over year.
Medicamen Biotech Limited Return on Equity (ROE) for the year ending March 31, 2021 was 9.13%, a -16.76% change year over year.
Medicamen Biotech Limited Return on Equity (ROE) for the year ending March 31, 2020 was 10.96%, a -21.01% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NSE: MEDICAMEQ.NS

Medicamen Biotech Limited

CEO	Mr. Rajesh Madan B. Pharma
IPO Date	Oct. 27, 2021
Location	India
Headquarters	1506, Chiranjiv Tower
Employees	378
Sector	Consumers Staples
Industries Personal Care Cleaning Supplies Cosmetics Dental Care Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Pharmaceuticals

Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

Key trends

Past 5 years